Loading clinical trials...
Loading clinical trials...
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Conditions
Interventions
Pegilodecakin
FOLFOX
Locations
130
United States
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Cancer Treatment Centers of America
Goodyear, Arizona, United States
University of Arizona Cancer Center
Phoenix, Arizona, United States
Comprehensive Blood and Cancer Center
Bakersfield, California, United States
St. Joseph Heritage Healthcare
Fullerton, California, United States
USC Norris Cancer Hospital
Los Angeles, California, United States
Start Date
March 1, 2017
Primary Completion Date
September 9, 2019
Completion Date
March 5, 2020
Last Updated
October 19, 2020
NCT06423326
NCT07542041
NCT07283705
NCT07438106
NCT03937453
NCT05053971
Lead Sponsor
Eli Lilly and Company
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions